<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02400307</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-141-1479</org_study_id>
    <secondary_id>2015-000898-12</secondary_id>
    <nct_id>NCT02400307</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of GS-9883 in Adults With Normal and Impaired Renal Function</brief_title>
  <official_title>A Phase 1, Open-Label, Parallel-Group, Adaptive Single-dose Study to Evaluate the Pharmacokinetics of GS-9883 in Subjects With Normal and Impaired Renal Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the pharmacokinetic (PK) profile, safety, and tolerability of oral
      GS-9883 in adults with impaired renal function relative to matched, healthy controls with
      normal renal function. Each participant in the renal impairment groups will be matched for
      age (± 10 years), gender, and body mass index [BMI (± 20%, 18 ≤ BMI ≤ 40 kg/m^2)] with a
      participant in the control group.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the concentration-time curve extrapolated to infinite time (AUCinf) for GS-9883</measure>
    <time_frame>Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve from zero to the last quantifiable concentration (AUC_0-last) for GS-9883</measure>
    <time_frame>Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) of GS-9883</measure>
    <time_frame>Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 1</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-emergent adverse events (AEs) and treatment-emergent laboratory abnormalities</measure>
    <time_frame>Up to 31 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>Severe Renal Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with severe renal impairment and matched healthy controls will receive a single dose of GS-9883.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moderate Renal Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with moderate renal impairment and matched healthy controls will receive a single dose of GS-9883.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mild Renal Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with mild renal impairment and matched healthy controls will receive a single dose of GS-9883.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GS-9883</intervention_name>
    <description>GS-9883 75 mg tablet administered orally</description>
    <arm_group_label>Severe Renal Impairment</arm_group_label>
    <arm_group_label>Moderate Renal Impairment</arm_group_label>
    <arm_group_label>Mild Renal Impairment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All Individuals:

               -  Must have a calculated BMI from 18 to 40 kg/m^2, inclusive, at screening

          -  Individuals with impaired renal function

               -  Chronic stable renal impairment without recent clinical change

                    -  Mild: Creatinine clearance (CrCl) = 60 - 89 mL/min

                    -  Moderate: CrCl = 30 - 59 mL/min

                    -  Severe: CrCl = 15 - 29 mL/min

          -  Healthy individuals

               -  CrCl ≥ 90 mL/min

        Exclusion Criteria:

          -  All Individuals:

               -  Pregnant or lactating females

               -  HIV positive or chronic hepatitis B infected

          -  Individuals with impaired renal function

               -  Chronic liver disease

               -  Dialysis or anticipated use of dialysis

               -  Renal transplant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Devi SenGupta, MD</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Avail Clinical Research</name>
      <address>
        <city>DeLand</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Pharmacology of Miami, Inc.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33014-3616</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orlando Clinical Research Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prism Clinical Research</name>
      <address>
        <city>St. Paul</city>
        <state>Minnesota</state>
        <zip>55114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Orleans Center for Clinical Research</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Auckland Clinical Studies Limited</name>
      <address>
        <city>Grafton</city>
        <state>Auckland</state>
        <zip>1010</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christchurch Clinical Studies Trust</name>
      <address>
        <city>Christchurch</city>
        <zip>8011</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>New Zealand</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 17, 2015</study_first_submitted>
  <study_first_submitted_qc>March 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 27, 2015</study_first_posted>
  <last_update_submitted>September 18, 2015</last_update_submitted>
  <last_update_submitted_qc>September 18, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase 1</keyword>
  <keyword>Renally Impaired</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

